Consolidated Statements of Cash Flows - USD ($)
$ in Thousands |
12 Months Ended |
Oct. 31, 2020 |
Oct. 31, 2019 |
Oct. 31, 2018 |
| Cash flows from operating activities: |
|
|
|
| Net loss |
$ (89,107)
|
$ (77,568)
|
$ (47,334)
|
| Adjustments to reconcile net loss to net cash (used in) provided by operating activities: |
|
|
|
| Share-based compensation |
1,868
|
2,804
|
3,238
|
| Depreciation and amortization |
19,377
|
12,353
|
8,648
|
| Change in fair value of common stock warrant liability |
37,086
|
0
|
0
|
| Gain on extinguishment of financing obligation |
(1,801)
|
0
|
0
|
| Gain on Series 1 preferred stock extinguishment |
(475)
|
0
|
0
|
| Non-cash interest expense on preferred stock and debt obligations |
7,570
|
6,097
|
5,957
|
| Deferred income taxes |
0
|
0
|
(3,035)
|
| Operating lease costs |
1,451
|
0
|
0
|
| Operating lease payments |
(1,016)
|
0
|
0
|
| Impairment of property, plant and equipment and project assets |
2,417
|
20,360
|
0
|
| Unrealized loss on derivative contract |
314
|
624
|
0
|
| Other non-cash transactions |
674
|
511
|
597
|
| Decrease (increase) in operating assets: |
|
|
|
| Accounts receivable |
(6,271)
|
4,842
|
24,169
|
| Unbilled receivables |
(5,590)
|
(4,488)
|
24,562
|
| Inventories |
(2,111)
|
(6,427)
|
31,714
|
| Other assets |
(1,297)
|
2,120
|
(2,264)
|
| Increase (decrease) in operating liabilities: |
|
|
|
| Accounts payable |
(7,059)
|
(173)
|
(19,846)
|
| Accrued liabilities |
5,465
|
2,377
|
(11,345)
|
| Deferred revenue |
1,724
|
5,996
|
1,261
|
| Net cash (used in) provided by operating activities |
(36,781)
|
(30,572)
|
16,322
|
| Cash flows from investing activities: |
|
|
|
| Capital expenditures |
(382)
|
(2,151)
|
(10,028)
|
| Project asset expenditures |
(31,527)
|
(31,675)
|
(41,232)
|
| Asset acquisition |
(611)
|
(35,474)
|
0
|
| Net cash used in investing activities |
(32,520)
|
(69,300)
|
(51,260)
|
| Cash flows from financing activities: |
|
|
|
| Repayment of debt |
(30,117)
|
(48,395)
|
(16,616)
|
| Proceeds from debt, net of debt discount |
87,757
|
69,596
|
13,091
|
| Common stock issued for stock plans and related expenses |
5
|
23
|
0
|
| Payment of deferred financing costs |
(2,697)
|
(3,302)
|
(352)
|
| Proceeds from sale of common stock and warrant exercises, net |
173,194
|
43,573
|
10,455
|
| Payment of preferred dividends and return of capital |
(6,475)
|
(1,840)
|
(4,178)
|
| Net cash provided by financing activities |
221,667
|
59,655
|
27,717
|
| Effects on cash from changes in foreign currency rates |
(92)
|
(244)
|
12
|
| Net increase (decrease) in cash, cash equivalents, and restricted cash |
152,274
|
(40,461)
|
(7,209)
|
| Cash, cash equivalents, and restricted cash-beginning of year |
39,778
|
80,239
|
87,448
|
| Cash, cash equivalents, and restricted cash-end of year |
192,052
|
39,778
|
80,239
|
| Series D Preferred Stock [Member] |
|
|
|
| Cash flows from financing activities: |
|
|
|
| Net proceeds from issuance of preferred shares |
$ 0
|
$ 0
|
$ 25,317
|